Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS235 in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
NCT07123779Phase 2Recruiting
- Sponsor
- 35Pharma
- Start
- Oct 2026
- Primary completion
- Jan 2029
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of HS235 in pulmonary hypertension (PH), heart failure with preserved ejection fraction (HFpEF), sponsored by 35Pharma. Started Oct 2026; status: recruiting.
02
Drugs
HS235
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07123779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123779.